Skip to main content

Advertisement

SpringerLink
Log in

Is it time for personalized therapy in IgA nephropathy patients?

  • Commentary
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

A Correction to this article was published on 08 December 2023

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

No datasets were used.

Change history

References

  1. Roccatello D, Careddu A, Ferro M et al (2023) The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy. J Nephrol. https://doi.org/10.1007/s40620-023-01636-6

    Article  PubMed  PubMed Central  Google Scholar 

  2. Trimarchi H, Barratt J, Cattran DC et al (2017) IgAN classification Working Group of the International IgA nephropathy Network and the Renal Pathology Society; Conference Partecipants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 91:1014–1021

    Article  PubMed  Google Scholar 

  3. Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100:753–779

    Article  PubMed  Google Scholar 

  4. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446

    Article  CAS  PubMed  Google Scholar 

  5. Heerspink HJL, Radhakrishnan J, Alpers CE et al (2023) Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401:1584–1594

    Article  CAS  PubMed  Google Scholar 

  6. Komers R, Gipson DS, Nelson P et al (2017) Efficacy and Safety of Sparsentan compared with Irbesartan in patients with Primary Focal Segmental Glomerulosclerosis: randomized, Controlled Trial Design (DUET). Kidney Int Rep 2:654–664

    Article  PubMed  PubMed Central  Google Scholar 

  7. Peng XJ, Zheng WM, Huang YH et al (2021) Efficacy and safety of mycophenolate mofetil in treatments for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Exper Nephrol 25:788–801

    Article  CAS  Google Scholar 

  8. Hou FF, Xie D, Wang J et al (2023) Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy. A randomized clinical trial. JAMA Netw Open 6:e2254054

    Article  PubMed  Google Scholar 

  9. Schena FP, Tripepi G, Rossini M et al (2021) Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy. Clin Kidney J 15:895–902

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was funded by Ministero dell'Università to Schena Francesco Paolo with Grant number ARS01_00876.

Author information

Authors and Affiliations

  1. Department of Personalized Medicine, University of Bari, Bari, Italy

    Francesco Paolo Schena

  2. Department Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Bari, Italy

    Sharon Natasha Cox

Authors
  1. Francesco Paolo Schena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharon Natasha Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Paolo Schena.

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical approval

There are no human participants.

Informed consent

Not necessary.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article has been updated: Due to author given name and family name update.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 35 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schena, F.P., Cox, S.N. Is it time for personalized therapy in IgA nephropathy patients?. J Nephrol 36, 2171–2173 (2023). https://doi.org/10.1007/s40620-023-01745-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-023-01745-2

keywords

Search

Navigation